RE:RE:RE:any chance we could talk about the actual Company here?I didn't hear them indicate whether a recording will be available (but I did join a few minutes late and didn't listen to the operator at the end of the call).
Note, they were talking pretty fast so my notes may not be entirely accurate.
They started the call by giving a comparison of this years Q1 to last years Q1. Big percentage increases in revenue, eps, net profit (91% increase i think, not including transaction costs), and net assets compared to Q1 last year. Product lines increased from 1 to 7. Currently, approximately $8.5 million in cash and $2.5 million (I think, too lazy to check financials) in receivables.
Talked a lot about their focus on cross-selling. It takes time, so will not show up in the results right away.
Going forward, they want to improve communication to shareholders. Right now focused on growing the business, but will start to focus more on providing shareholders with more exact figures after an acquisition (e.g. how much EPS will increase, how many patients can be targeted for cross-selling, etc.). In addition, future reports should provide shareholders with more detail on the different product lines such as targets.
Indiacted that although the balance sheet is in good shape, they will issue some equity as part of future acquisitions because they want the sellers to be shareholders. Noted that they could probably add $20 million in revenue by doing acquisition with their current balance sheet (although I'm sure they would issue equity as well).
Although early, this year they are on track for approximately $15 million in revenue.
Payment cycle for patients: Medicare pays the bills for most patients (which is a 60 day payment cycle). Private insurance usually pays a portion as well which can add a few weeks. Bad debt is usually the amounts leftover that are personally owed by the patients.
Talked a lot about the Coumadin and COPD product lines. My notes aren't great on this stuff so I'm not confident it is accurate. I beleive they said that 1 COPD patient is equal to 8 Coumadin patients (i.e. COPD is high margin). Thinks the acquisition of HHC will double Coumadin patients. Don't have very many COPD patients right now because this product line is so young, but it is very high margin (I think they said 60 something %).